美国预防合格偏头痛患者的人口统计学和临床特征：一项全国性调查和行政索赔数据库研究。

Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: a linked national survey and administrative claims database study.

机构信息

Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA.

Kantar Health, New York, NY, USA.

出版信息

Curr Med Res Opin. 2021 Mar;37(3):443-457. doi: 10.1080/03007995.2020.1865749. Epub 2021 Jan 15.

DOI:10.1080/03007995.2020.1865749

PMID:33331205

Abstract

OBJECTIVE

To characterize burden of migraine in prevention-eligible patients compared with prevention non-eligible patients in the United States (US). Receipt of preventive therapy was also examined among prevention-eligible patients.

METHODS

This retrospective study utilized data from the 2017 US National Health and Wellness Survey linked with medical and pharmacy claims. Patients aged ≥18 years who self-reported experiencing migraine and had confirmed evidence of migraine (≥1 medical or pharmacy claim) were included. Prevention eligibility was based on number of headache days in the past 30 days (prevention-eligible: ≥4 and prevention non-eligible: <4). Descriptive statistics summarized study variables; bivariate and multivariable analyses were conducted to examine the association of prevention-eligibility status with outcomes.

RESULTS

Analyses included 450 patients, 291 (65%) prevention-eligible, and of these 56 (19%) received preventive therapy. Overall, patients were 42.98 ± 14.51 years old; 84% were female. Prevention-eligible patients reported significantly more migraine headache days in the past 6 months (29.27 ± 37.96 vs. 8.61 ± 7.88), had lower mental component summary scores (35.80 ± 2.73 vs. 37.90 ± 2.96), and more presenteeism (47.30 ± 2.98% vs. 37.90 ± 2.60%), overall work impairment (46.30 ± 2.87% vs. 37.90 ± 2.55%) and activity days missed due to migraine (8.16 ± 3.05 vs. 3.82 ± 1.58) than prevention non-eligible patients (all <.001). Prevention-eligible patients receiving preventive therapy reported more migraine headache days during the past month (9.21 ± 7.99 vs. 6.06 ± 7.10; =.002) and activity days lost due to migraine (18.39 ± 28.08 vs. 10.69 ± 21.43, =.015) than those not receiving preventive therapy.

CONCLUSIONS

Prevention-eligible patients experience greater burden due to migraine, including more headache days, worse health-related quality-of-life, and greater work and activity impairment than prevention non-eligible patients.

摘要

目的

描述美国（美国）中预防合格患者与预防不合格患者偏头痛负担的特征。还检查了预防合格患者中预防性治疗的应用情况。

方法

这项回顾性研究利用了 2017 年美国国家健康和健康调查的数据，并与医疗和药房索赔进行了关联。纳入年龄≥18 岁，自我报告有偏头痛发作并经证实有偏头痛（≥1 项医疗或药房索赔）的患者。根据过去 30 天的头痛天数确定预防资格（预防合格：≥4 天，预防不合格：<4 天）。描述性统计总结了研究变量；进行了单变量和多变量分析，以检查预防合格状况与结局之间的关联。

结果

分析包括 450 名患者，其中 291 名（65%）为预防合格，其中 56 名（19%）接受了预防性治疗。总体而言，患者的年龄为 42.98±14.51 岁；84%为女性。预防合格的患者在过去 6 个月中报告的偏头痛头痛天数明显更多（29.27±37.96 比 8.61±7.88），精神成分综合评分较低（35.80±2.73 比 37.90±2.96），并且更经常出现旷工（47.30±2.98%比 37.90±2.60%），整体工作能力下降（46.30±2.87%比 37.90±2.55%）和因偏头痛错过的活动天数（8.16±3.05 比 3.82±1.58）比预防不合格的患者多（均<.001）。接受预防性治疗的预防合格患者在过去一个月内报告的偏头痛头痛天数更多（9.21±7.99 比 6.06±7.10；=.002），因偏头痛而失去的活动天数更多（18.39±28.08 比 10.69±21.43；=.015），而未接受预防性治疗的患者。